A major maker shrinks list prices — but access is complex Novo Nordisk announced plans to cut U.S. list prices for its GLP‑1 diabetes and weight‑loss drugs by as much as half starting in 2027. The move affects headline prices for products like Wegovy and Ozem…
Novo Nordisk announced plans to cut U.S. list prices for its GLP1 diabetes and weightloss drugs by as much as half starting in 2027. The move affects headline prices for products like Wegovy and Ozem… [+1475 chars]
